Caplin Point Laboratories Limited (BOM: 524742)
India
· Delayed Price · Currency is INR | Market Cap | 152.79B |
| Revenue (ttm) | 17.58B |
| Net Income (ttm) | 4.78B |
| Shares Out | 76.01M |
| EPS (ttm) | 62.59 |
| PE Ratio | 32.11 |
| Forward PE | 29.68 |
| Dividend | 5.00 (0.25%) |
| Ex-Dividend Date | Sep 23, 2024 |
| Volume | 6,911 |
| Open | 2,008.00 |
| Previous Close | 2,008.45 |
| Day's Range | 1,999.00 - 2,049.00 |
| 52-Week Range | 950.00 - 2,158.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Caplin Point Laboratories
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point La... [Read more]
Financial Performance
In 2023, Caplin Point Laboratories's revenue was 16.94 billion, an increase of 15.38% compared to the previous year's 14.68 billion. Earnings were 4.57 billion, an increase of 21.48%.
Financial StatementsNews
Caplin Point shares hit 52-week high, surge over 7%
As of 9:58 AM, the stock was trading at ₹2,107.55, marking a significant increase of ₹138.70 or 7.04% from its previous close. This surge propelled the stock to breach its previous 52-week high, setti...
Caplin Point shares surge 5% after Brazilian regulator clears Tamil Nadu facility
Caplin Point Laboratories’ shares saw a significant rise of over 5% after the Brazilian Health Regulatory Agency (ANVISA) gave a green light to the company’s manufacturing facility in Tamil Nadu. The ...